WRNA:XETRA:XETRA-WisdomTree BioRevolution UCITS ETF - USD Acc (EUR)

ETF | Others |

Last Closing

USD 15.74

Change

-0.03 (-0.18)%

Market Cap

USD 2.77M

Volume

200.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.01 (-0.02%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.08%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.09%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.02 (-0.07%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.09 (+0.35%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.29%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.13%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.12%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.50 (-0.50%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.84 (-0.32%)

USD 80.38B

ETFs Containing WRNA:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.32% 8% B- 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.32% 9% A- 19% F
Trailing 12 Months  
Capital Gain 13.96% 43% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.96% 43% F 49% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.26% 8% B- 11% F
Dividend Return -5.26% 7% C- 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.82% 70% C- 76% C+
Risk Adjusted Return -67.29% 7% C- 7% C-
Market Capitalization 2.77M 2% F 1% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.